Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab + Loncastuximab Tesirine in R/R Large B-cell Lymphoma
NCT06919939Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Jan 2026
- Primary completion
- Jan 2031
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab, loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Miami. Started Jan 2026; status: recruiting.
02
Drugs
epcoritamabloncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06919939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919939.